Guideline for office spirometry in adults, 2012

C F N Koegelenberg, F Swart, E M Irusen

Division of Pulmonology, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town
C F N Koegelenberg, MB ChB, MMed (Int), FCP (SA), MRCP (UK), Cert Pulm (SA), PhD
F Swart, NDClinTech (SA)
E M Irusen, MB ChB, FCP (SA), PhD

Background. Office spirometry remains an integral part of a comprehensive respiratory evaluation and is used to categorise the nature, severity and progression of respiratory diseases and to measure response to treatment. These updated guidelines are aimed at improving the quality, standardisation and usefulness of office spirometry in South Africa.

Recommendations. All equipment should have proof of validation regarding resolution and the system’s linearity (consistency). Moreover, equipment must be calibrated daily and quality controlled. It is also important to have standard operating procedures in place, including the documentation of ambient conditions and infection control measures.

Adequate spirometry relies on a competent operator, accurate equipment, standardised operating procedures, quality control and patient co-operation. The indication for spirometry in a particular patient should be unambiguous and should be documented. Subjects should be appropriately prepared for testing, and patient details must be documented. Forced vital capacity (FVC) manoeuvres (either closed or open circuit) must be performed strictly according to guidelines, and strict quality assurance methods should be in place, including acceptability criteria (for any given effort) and repeatability (between efforts). Testing should continue until at least 3 acceptable curves are produced (with 2 fulfilling repeatability criteria). Other indices are derived from these efforts.

Conclusion. Test results must be categorised and graded according to current guidelines, taking into account the indication for the test and the appropriateness of reference values.


1. Introduction

Pulmonary function testing is used to categorise the nature, severity and progression of respiratory disorders and to measure the patient’s response to therapy. Office spirometry remains an integral part of a comprehensive respiratory evaluation and is often used as an adjunct to the diagnosis of asthma and chronic obstructive pulmonary disease (COPD) and to screen for occupational lung diseases.1,2 However, improper standards and operating procedures significantly reduce its value in the diagnosis of and screening for these conditions.1,2

Adequate spirometry relies on a competent operator, accurate equipment, standardised operating procedures (SOPs), quality control and patient co-operation.1,2 Moreover, appropriate and validated reference standards must be used.1,2 Spirometry should always be viewed within the clinical context, and not as a stand-alone investigation.1

The most recent South African guideline for office spirometry in 20042 has been superseded by comprehensive international guidelines.2,3 Furthermore, there is a growing body of evidence regarding local reference standards.2,3 This article aims to provide an updated and simplified guideline for the use of office spirometry at the primary healthcare level.

2. Basic equipment and definitions

2.1 Spirometry

Spirometry involves the measurement of the air volumes and airflow rates of the lung. These are dependent on the physical properties of the airways, lung parenchyma, pleura and chest wall and the strength of respiratory muscles.1,3 Practically all modern commercially available computerised spirometers are flow-type spirometers that use a flow-sensor (pneumotach) to derive volumes.2 They can display expiratory and inspiratory manoeuvres in real time as flow-volume loops, allowing instant pattern recognition.

Modern equipment also automatically superimposes measured volume-time curves.2,3 Flow-volume curves (from newer flow-type spirometers) and flow-volume loops can be generated automatically in real time, allowing instant pattern recognition.

2.2 Measurements

The minimum measurements that basic office spirometers should produce include:

- Forced vital capacity (FVC): The maximum volume of gas exhaled from the position of maximal inspiration by means of a rapid, maximally forced expiratory effort, expressed in litres (body temperature and ambient pressure, saturated with water vapour) (BTPS). BTPS refers to a standardised volume at normal body temperature (37°C) at ambient pressure, saturated with water vapour.
- Forced expiratory volume (FEV): The volume of gas exhaled during the first second of the FVC manoeuvre, expressed in litres (BTPS).
53 January 2013, Vol. 103, No. 1 SAMJ

2.3 Accuracy, repeatability and reproducibility

Accuracy is the truthfulness or closeness of agreement between the result of a measurement and the true value.\(^3\)

Repeatability is the closeness of agreement (precision) between the results of successive measurements of the same patient (provided that the same methods, instrument, observer and conditions are present for these measurements).

Reproducibility is the closeness of agreement of the results of successive measurements of the same item where the measurements are carried out with changed conditions (e.g. methods, observer, instrument, location, conditions of use, or time).\(^3\)

2.4 Measurement range and equipment resolution

The measurement range is the range over which the manufacturer indicates that the device complies with the equipment resolution, which is the smallest detectable change in measurement.\(^3\)

2.5 Calibration and validation

Calibration is the process whereby a device’s accuracy and repeatability are tested and corrected using a gold standard, e.g. a calibration syringe with standard volumes. Validation is the process of establishing and certifying that the device is correctly calibrated.

3. Indications for spirometry

The indications for spirometry in a particular patient should be unambiguous and should be documented in each case. Indications include:\(^2,4\)

- Diagnostic • evaluating abnormal respiratory symptoms and signs (in individuals with suspected obstructive and/or restrictive lung diseases)
- Evaluating the extent to which a disease affects the respiratory system • measuring the extent to which a disease affects the respiratory system
- Screening individuals at risk, e.g. smokers, employees exposed to substances known to cause respiratory disease • screening individuals at risk, e.g. smokers, employees exposed to substances known to cause respiratory disease
- Preoperative risk assessment • preoperative risk assessment
- Assessing prognosis • assessing prognosis
- Monitoring • monitoring
- Public health • rehabilitation
- Medico-legal cases • medico-legal cases
- Epidemiological surveys and derivation of reference equations.

4. Specifications and technical preparation for spirometry

4.1 Validation

All equipment should have proof of validation.\(^2,4\) Accuracy depends on the system’s resolution (minimum detectable volume or flow) and linearity (consistency), from the measuring components to the display and graphical output.

The European Respiratory Society/American Thoracic Society (ERS/ATS) Taskforce for the Standardisation of Lung Function Testing has recommended minimum performance criteria for spirometers, and guidelines for validating equipment using waveform-generated calibration syringes\(^5\) (Tables 1 and 2). Other recommendations include:
4.2 Calibration and equipment quality control

To ensure that they remain accurate during use, all diagnostic spirometers must be volume-calibrated at least daily, using a calibrated syringe with a volume of at least 3 l. In some settings (e.g. industrial surveys), the calibration should be performed twice daily. Moreover, calibration should be repeated if the temperature changes markedly over the course of a day.

Flow-type spirometers should be calibrated with at least 3 discharges to give a range of flows from 0.5 l/s to 12 l/s (with the 3 l syringe this equates to times of approximately 6 s and <0.5 s). This must be done with the machine switched to calibration mode, to prevent BTPS-correction because room air has been injected. Also enter ambient temperature and barometric pressure readings, which may be obtained from the local airport or weather bureau.

• a BTPS-correction facility. The volume of exhaled gas is measured outside the body at ambient conditions, designated ambient temperature and pressure, saturated with water vapour (ATPS). This facility corrects these measurements to reflect conditions inside the lung (BTPS). Without it, volumes have to be corrected manually. Depending on the environmental temperature, the BTPS correction factor may be as large as 10%. Ambient temperature, barometric pressure and time of day should therefore be recorded.

• the facility to generate real-time spiromgrams, in order to enhance feedback and subject compliance
• stating the source(s) of reference values, combined with the facility to select or enter appropriate values manually
• computer-driven technical quality indicators that meet ERS/ATS standards
• printing or electronic facility for record-keeping purposes
• adequate ability to save large numbers of tests and test quality indicators where needed, e.g. for occupational surveillance.

4.3 Ambient conditions

Ambient temperature, barometric pressure and time of day should be recorded daily. Temperature is a significant variable in spirometry, and may be measured directly by a simple thermometer or internal thermostat (i.e. directly by the equipment). It is the responsibility of the operator to confirm the accuracy of temperature measurements, and the manufacturer’s responsibility

Guideline

Table 1. Selective minimum volume and flow criteria for diagnostic spirometers

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Volume range (l)</th>
<th>Accuracy*</th>
<th>Repeatability†</th>
<th>Flow range (l/s)</th>
<th>Time (s)</th>
<th>Validation method</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC</td>
<td>0.5 - 8.0</td>
<td>+/- 3% of reading or +/- 0.050 l, whichever is greater</td>
<td>+/- 4.5% of reading or +/- 0.200 l, whichever is greater</td>
<td>0 - 14</td>
<td>30</td>
<td>24 ATS waveforms, 3l calibration syringe</td>
</tr>
<tr>
<td>FEV1</td>
<td>0.5 - 8.0</td>
<td>+/- 3% of reading or +/- 0.050 l, whichever is greater</td>
<td>+/- 4.5% of reading or +/- 0.200 l, whichever is greater</td>
<td>0 - 14</td>
<td>1</td>
<td>24 ATS waveforms</td>
</tr>
<tr>
<td>PEF</td>
<td>NA</td>
<td>+/- 10% of reading or +/- 0.30 l/s, whichever is greater</td>
<td>+/- 5% of reading or 0.15 l/s, whichever is greater</td>
<td>0 - 14</td>
<td></td>
<td>24 ATS flow waveforms</td>
</tr>
</tbody>
</table>

*Percentage deviation = 100 x (average-standard)/standard.
†Percentage span = 100 (maximum-minimum)/average.

Table 2. Minimum scale for spiromogs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Required resolution</th>
<th>Scaling</th>
<th>Required resolution</th>
<th>Graphical output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.050 l</td>
<td>5 mm/l</td>
<td>0.025 l</td>
<td>10 mm/l</td>
</tr>
<tr>
<td>Flow</td>
<td>0.200 l/s</td>
<td>2.5 mm/l/s</td>
<td>0.100 l/s</td>
<td>5 mm/l/s</td>
</tr>
<tr>
<td>Time</td>
<td>0.2 s</td>
<td>10 mm/s</td>
<td>0.2 s</td>
<td>20 mm/s</td>
</tr>
</tbody>
</table>

*The correct aspect ratio for a flow v. volume display is two units of flow per one unit of volume.
5. Hygiene and infection control

5.1 Rationale
There is a small but real risk of transmitting infections to test subjects and staff during pulmonary function testing. Practically all the components of the spirometry system have been implicated, and transmission can occur through direct and indirect contact. Upper respiratory diseases, enteric infections and blood-borne infections can be transmitted through direct contact. Hepatitis and HIV transmission becomes possible if patients suffer from open oral mucosal ulcers or possible bleeding gums. Tuberculosis and various viral and bacterial infections can potentially be transmitted via indirect contact through aerosol droplets. Mouthpieces and the immediately proximal surfaces of valves or tubing are the most likely sources of contamination in the last two instances. The type of test manoeuvre used (and specifically whether the patient inhales from the spirometer) significantly influences the extent of infection control needed. Using an inspiratory manoeuvre only, without inhalation from the spirometer, reduces the potential for cross-contamination and is the method of choice for mass screening purposes.

5.2 Infection control recommendations
Transmission to operators can be prevented by proper hand-washing and using barrier devices, e.g. gloves. Hands should be washed following direct handling of mouthpieces, tubing, valves or interior spirometer surfaces and always between patients. Operators who have open cuts or lesions on their hands should wear gloves, particularly when handling contaminated equipment.

Cross-contamination should be avoided. Mouthpieces, nose clips and any other equipment that comes into direct contact with mucosal surfaces should be disinfected, sterilised or discarded (if disposable) after each use. Any equipment surface (tubing, valves or manifolds) showing condensation from expired air should be disinfected or sterilised before re-use. Manufacturers’ recommendations should be adhered to, particularly regarding the choice of sterilising agents, as some equipment may be damaged by chemicals or heat.

Between subjects, volume-based spirometers used with a closed-circuit technique should be flushed with room air at least 5 times over the spirometer’s entire volume range to ensure clearance of droplet nuclei. The breathing tube and mouthpiece should be decontaminated or changed between patients.

When an open circuit (either volume or flow spirometers) is used, only the portion of the circuit through which rebreathing occurs must be decontaminated between patients, as long as the subject only exhales into the spirometer.

With inhalation, however, additional measures must be put in place: after each subject either in-line disposable filters must be used and replaced, or the involved parts of the system (spirometer, breathing tubes and resistive element of the pneumotach) must be decontaminated/sterilisedflushed. Most units employ in-line filters, as re-calibration is necessary every time a system has been dismantled for decontamination.

Special precautions must be taken for patients with known transmissible infections such as tuberculosis, or those with current haemoptysis. In-line filters should be used routinely (even if expiratory manoeuvres are performed exclusively), and after each use contaminated surfaces should be sterilised and equipment decontaminated. Proper attention should also be paid to environmental control, e.g. ventilation. Practical considerations include testing such cases at the end of the day (to allow overnight decontamination of equipment).

6. Patient considerations and preparation
The patient’s gender, age, race, standing height and weight must be recorded on the day of the test, as these variables (particularly gender, race and height) are required for reference purposes. Height (and weight) should be measured with the subject barefoot (feet together), wearing only light clothing and looking straight ahead. The body mass index (kg/m²) should be calculated. Smoking status and the use of any medication that can influence spirometry should be documented, including the type and dose of drugs and when they were last administered.

6.1 Contraindications
There are few absolute contraindications for spirometry. A major exclusion criterion in routine practice is current respiratory infections in individuals participating in impairment/disability assessment, as respiratory infections can temporarily impair lung function. The current ATS/ERS guideline also recommends that lung function testing should not be performed within one month of a myocardial infarction. Situations where suboptimal testing is likely include chest and abdominal pain, facial discomfort exacerbated by a mouthpiece, stress incontinence, dementia or an acute confusional state. Patients with severe emphysema who experience syncope with forced and prolonged expiration should not be retested.

6.2 Subject preparation
Patients should abstain from smoking (within 1 hour) and consuming alcohol (within 4 hours) of testing, and should not perform any vigorous exercise 30 minutes before testing. Clothing that restricts chest and abdominal movement and a large meal within 2 hours of testing should also be avoided. Patients should be informed of these requirements prior to testing, and deviations should be documented.

Subjects should be relaxed and comfortable before and during testing. Tight-fitting clothing should be loosened and distractions minimised. Well-fitting dentures can be left in place but loose-fitting ones are best removed. The use of a nose clip is strongly recommended.

It is imperative to use simple instructions to ensure optimum co-operation, which may include real-time visual aids. Patients should be given feedback regarding their performance and continuously encouraged (including descriptions of potential improvements that can be made).

6.3 Subject positioning
Spirometry may be performed either sitting or standing (the position should be reported). The sitting position is the most widely used, mainly because of the risk of syncope during forced expiration. The chair should have arm rests, but no wheels. Patients with central obesity may achieve deeper inspiration while standing, and thus have higher volumes and flows when tested in this position.

7. Execution of tests
7.1 FVC and FEV₁, test manoeuvres
The operator should follow the summarised procedures (Table 3). The performance of an FVC manoeuvre has 3 distinct phases: (i) maximal inspiration; (ii) rapid, forceful exhalation (a ‘blast’); and (iii) continued complete exhalation to the end of test (EOT). There are essentially two accepted procedures:

- **Closed circuit method.** This allows the recording of inspiration and expiration, and generation of flow-volume loops (on a flow-type spirometer). The subject assumes the correct posture, a nose clip is attached, and a mouthpiece is inserted around which the subject closes their lips. The subject...
Table 3. Procedures for recording FVC

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Criteria</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verify spirometer calibration</td>
<td>Enquire about medication use and smoking status</td>
<td>Measure weight and height</td>
</tr>
<tr>
<td>Explain the procedure</td>
<td>Correct positioning and posture</td>
<td>Complete and rapid inspiration</td>
</tr>
<tr>
<td>Instruct and demonstrate test</td>
<td>Correct positioning and posture</td>
<td>Forced, maximal exhalation</td>
</tr>
<tr>
<td>Perform manoeuvre</td>
<td>Closed v. open circuit (see text)</td>
<td>Repeat instructions as necessary</td>
</tr>
<tr>
<td>Verify test quality</td>
<td>Acceptability</td>
<td>Repeat for a minimum of 3 tests</td>
</tr>
<tr>
<td>Perform more attempts</td>
<td>Maximum of 8</td>
<td></td>
</tr>
</tbody>
</table>

*Adapted from Miller et al.*

is instructed to inhale completely and rapidly with a pause of <1 s at total lung capacity (TLC), followed by rapid, forceful and maximal exhalation until no further air can be expelled (maintaining an upright posture).

- **Open circuit (expiration-only) method.** This is often employed for mass screening, and consists of an FVC test with or without a slow VC test. After the subject assumes the correct posture, a clip is attached to their nose. The subject is required to inhale completely and rapidly with a pause of <1 s at TLC. Theretofore a mouthpiece is inserted and the lips must be closed around it. Expiration must be rapid, forceful and complete, lasting at least 6 s. A slow VC test is sometimes performed, as a reduction in the FVC compared with the slow VC suggests dynamic collapse of airways during forced expiration. The slow VC test is preceded by a maximal inspiration, the mouthpiece is inserted and the patient then breathes out in a relaxed fashion and for as long as possible.

7.2 Quality assurance

Many within-manoeuvre and between-manoeuvre criteria must be satisfied to ensure adequate quality:

- **Start and end of test.** The start of test (‘time zero’) should be determined by the back-extrapolation method (Fig. 2), and defines the start for all timed measurements. The steepest slope on the volume-time curve is used for manual measurements, whereas the largest slope averaged over an 80 ms period is used for computerised back-extrapolation. Current recommended EOT criteria include: (i) subjects cannot or should not continue further exhalation (due to discomfort or the risk of syncope); or (ii) the volume-time curve shows no change in volume (<0.025 l for ≥1 s); or (iii) the subject has attempted to exhale ≥6 s (≥3 s for children <10 years).

- **Acceptability criteria.** Table 4 summarises the within–manoeuvre acceptability criteria for the recording of FVC and FEV₁. Acceptable curves must satisfy all 7 criteria listed, whereas ‘usable’ curves only need a good start (without hesitation) and for the subject to be free of coughing during the first second (Figs 3 & 5).

- **Repeatability.** An adequate test requires a minimum of 3 acceptable FVC manoeuvres. Acceptable repeatability is achieved when the difference between the largest and the next largest FVC and FEV₁ is ≤0.150 l (Fig. 6). For patients with a VC of 1.0 l, this value is 0.100 l. If these criteria are not met after 3 attempts, additional testing should be performed, up to a maximum of 8 manoeuvres, or until the subject cannot or should not continue, or it is obvious that perseverance will not change the outcome. When repeatability is not achieved, results are labelled as such.

7.3 Test result selection

The FVC and FEV₁ should be measured from a series of at least 3 acceptable forced expiratory curves. The largest FVC and the largest FEV₁ (BTPS) should be recorded and used to determine other indices, even if they do not come from the same attempt.

7.4 Other derived indices

The PEF is obtained from flow-volume curve data, and should be reported. It is the maximum expiratory flow achieved from a maximum forced expiration, starting without hesitation from the point of maximal lung inflation, expressed in l/s. PEF should be achieved within the first 25% of the volume expired from maximum inspiration (most subjects can produce PEF within the first 15% of the volume expired.)

The FEF_{25-75} is also known as the maximum mid-expiratory flow, and has to be measured with an accuracy of at least +/- 5% of the reading or +/- 0.200 l/s, whichever is less, over a range of up to 7 l/s. It is dependent on the validity of the FVC measurement and the degree of expiratory effort.

7.5 Flow volume loops

In most laboratories, flow volume loops are generated in real-time during FVC and FEV₁ test manoeuvres. There are two acceptable approaches:

- The subject performs tidal breathing at FRC, and then, in one continuous sequence, performs a slow expiration to residual volume, followed immediately by a slow inspiration to TLC, and a rapid full expiration with maximal effort to RV (during which time FVC and FEV₁ are measured). This is immediately followed by a rapid full inspiration with maximum effort back to TLC. Both VC as well as FVC can be measured with this technique.
The subject takes a rapid full inspiration to TLC from room air through the mouth, thereafter a mouthpiece is inserted and then, without hesitation, an expiration with maximum force is performed until no more air can be expelled, followed by rapid maximum inspiration.4

The principles for within- and between-manoeuvre evaluation are the same as for FVC.

### 7.6 Reversibility testing

The purpose of a bronchodilator test is to determine whether airway obstruction, as measured by spirometry, is reversible with an inhaled bronchodilator (the choice of drug, dose and delivery mode is a

---

**Table 4. Within-manoeuvre acceptability criteria for the recording of FVC and FEV₁**

<table>
<thead>
<tr>
<th>No artefacts</th>
<th>Coughing during first second of expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Glottis closure (Valsalva manoeuvre) or hesitation</td>
</tr>
<tr>
<td></td>
<td>Early termination or submaximal effort</td>
</tr>
<tr>
<td></td>
<td>Leakage</td>
</tr>
<tr>
<td></td>
<td>Obstructed mouthpiece</td>
</tr>
</tbody>
</table>

| Good starts                | Extrapolated volume <5% of FVC or 0.150 l |
|----------------------------| (whichever is greater)                     |

| Exhalation                | At least 6 s (less only if the subject cannot or should not continue) |

*Adapted from Miller et al.*

---

**Fig. 3. Flow-volume curve exhibiting a cough artefact (X) that can influence observed forced vital capacity and FEV₁. Volume-time graphs are better for evaluating end-of-test quality.**

**Fig. 4. Flow-volume curve exhibiting glottis closure (X) resulting in premature termination of effort and reduced observed forced vital capacity.**

**Fig. 5. Flow-volume curve with a late peak. Failure to demonstrate reproducibility will confirm these as submaximal efforts.**
Clinical decision). A standard bronchodilator test is performed as follows:

1. The patient should abstain from using short-acting inhaled drugs at least 4 hours before testing. Long-acting bronchodilators and oral therapy with aminophylline should be stopped for 12 hours before the test. No smoking is allowed from one hour before testing and throughout the test procedure.

2. Three acceptable tests of FEV₁, FVC, and PEF (of which 2 are repeatable) should be performed.

3. A short-acting bronchodilator is administered. After a gentle expiration to FRC, a dose of 100 µg of salbutamol (or equivalent) is inhaled in one breath to TLC. The breath is then held for 10 s before exhaling. Four separate doses (total dose 400 µg) are delivered at 30 s intervals. Ipratropium bromide (total dose 4 x 40 = 160 µg) can be used as an alternative.

4. A waiting period of 10 - 15 minutes follows (30 minutes for ipratropium bromide).

5. A significant bronchodilator response is present if either the FEV₁ or FVC improve by 200 ml and 12%. Reversibility may be complete (when the post-bronchodilator values improve to at least 80% of predicted) or partial (when the post-bronchodilator values improve to less than 80% of predicted).

8. Interpretation and reporting of results

Observed results should always be compared with an appropriate reference population, and expressed as percentage observed/predicted. Predicted values for FVC and FEV₁ are calculated from equations based on age, height and gender, as these parameters are the major determinants of lung and airway size in healthy individuals. Practically all office spirometers are programmed with many prediction equations derived from the study of Europeans. The European Community for Steel and Coal (ECSC, Table 5) equations are the most widely used.

Most international guidelines for spirometry and the diagnosis and management of chronic respiratory conditions still advocate the use of 80% of predicted FVC and FEV₁ as suggested cut-off values, given the ease of calculation and interpretation. From a scientific perspective, however, the lower limit of normal (LLN) has a superior diagnostic accuracy.

The use of inappropriate predicted values can result in a falsely increased rate of abnormal results in clinically normal people. Evidence suggests that southern African indigenous populations, compared with Europeans, show similar or higher FEV₁/FVC% and a lower FVC and FEV₁ (up to 10%), but it has also been suggested that socio-economic variables may explain these observations.

In the past a correction factor of 0.9 for adjusting predicted values (FVC and FEV₁) was sometimes applied for black patients and those of Asian ancestry. In the absence of a large, all-inclusive study of the South African population, most local institutions currently use the European Community for Steel and Coal prediction equations without racial correction.

Local prediction equations are available (Table 6), but are rarely used, as they are not routinely included in the software packages of commercially available spirometers. Technically, however, these equations provide more accurate predicted values for screening for employment, compensation, surveillance and medico-legal purposes.

The interpreting clinician should be aware of these considerations and decide on the most appropriate reference equations for their practice, and whether racial adjustment is necessary.

8.1 Categorisation of spirometric results

The major aims of interpreting spirometry are to confirm a clinical diagnosis and to estimate the severity of the disease. The initial assessment is based on a suggested algorithm that employs three variables: FEV₁/FVC%, FVC (% predicted) and FEV₁ (% predicted). Pattern recognition (see below) can also aid in this assessment. Many still advocate an FEV₁/FVC% of <70% as indicative of obstruction, despite the fact that such a crude approach may lead to an under-diagnosis in young patients and an over-diagnosis in elderly patients.

An obstructive ventilatory defect is defined as a disproportionate reduction in maximal airflow from the lung, with regard to the maximal volume that can be displaced from the lung. Per definition, the FEV₁/VC...
Table 5. European Community for Steel and Coal prediction equations (valid for ages 18 - 70 years)

<table>
<thead>
<tr>
<th>Gender</th>
<th>Parameter</th>
<th>Prediction equation</th>
<th>RSD</th>
<th>LLN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>FVC (l)</td>
<td>$4.30H - 0.029A - 2.49$</td>
<td>0.84</td>
<td>Predicted value - (1.64 x RSD)</td>
</tr>
<tr>
<td></td>
<td>FEV(_1) (l)</td>
<td>$5.76H - 0.026A - 4.34$</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV(_1)/VC</td>
<td>$- 0.18A + 87.21$</td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>FVC (l)</td>
<td>$3.95H - 0.025A - 2.60$</td>
<td>0.62</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV(_1) (l)</td>
<td>$4.43H - 0.026A - 2.89$</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV(_1)/VC</td>
<td>$- 0.19A + 89.10$</td>
<td>10.7</td>
<td></td>
</tr>
</tbody>
</table>

RSD = residual standard deviation; LLN = lower limit of normal (lower 5th percentile); H = height standing in m; A = age in years (for ages 18 - 25, substitute age 25 in the equation).

(Adapted from Quanjer et al. 19)

Table 6. Prediction equations for South African blacks

<table>
<thead>
<tr>
<th>Gender</th>
<th>Parameter</th>
<th>Prediction equation</th>
<th>RSD</th>
<th>LLN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>FVC (l)</td>
<td>$2.9H - 0.027A - 0.54$</td>
<td>0.75</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV(_1) (l)</td>
<td>$4.8H - 0.024A - 3.08$</td>
<td>0.89</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>FVC (l)</td>
<td>$3.4H - 0.028A - 1.87$</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FEV(_1) (l)</td>
<td>$4.5H - 0.023A - 3.04$</td>
<td>0.67</td>
<td></td>
</tr>
</tbody>
</table>

RSD = residual standard deviation; LLN = lower limit of normal (lower 5th percentile); H = height standing in m; A = age in years (for ages 18 - 25, substitute age 25 in the equation).

(Adapted from Louw et al. 7 and Mokoetle et al. 10)

Fig. 7. An algorithm for the categorisation of spirometry. LLN = lower limit of normal.
is <LLN (lower 5th percentile). The expiratory limb of the flow-volume loop appears concave (Fig. 8), as flow per volume is reduced. PEF is reduced, as is the \( \text{FEF}_{25-75\%} \). FVC can be normal or reduced. **Obstruction with reduced VC** is most often due to air trapping, and the slow VC may be preserved in such cases. Moreover, plethysmography may then be indicated to evaluate the residual volume (RV), total lung capacity (TLC) and other parameters. A bronchodilator test should be performed in patients with an obstructive ventilatory defect, unless the indication for the test was purely screening, in which case the patient should be referred to a specialist.

A **restrictive ventilatory defect** is characterised physiologically by a reduction in TLC as determined by plethysmography (TLC per definition <lower 5th percentile), and can be inferred on spirometry when the \( \text{FEV}_{1}/\text{FVC\%} \) is normal or high and the FVC is reduced (Fig. 9). Several conditions can reduce FVC, including pulmonary pathology (e.g. interstitial fibrosis), chest wall and pleural disease (e.g. large effusions) and neuromuscular diseases. Flow is often relatively preserved in cases with pulmonary pathology (due to an increased elastic recoil), but decreased in other cases. Restrictive impairments are often over-diagnosed, chiefly because of poor effort and inappropriate reference values.

**Mixed obstructive-restrictive patterns** are sometimes seen, as some diseases (e.g. bronchiectasis) may produce both, and some patients may have dual pathology (e.g. COPD and interstitial pulmonary fibrosis). Both the \( \text{FEV}_{1}/\text{VC} \) and TLC should be <lower 5th percentile. It may be challenging to categorise a patient with a mixed pattern solely on the basis of spirometry, and to distinguish these cases from obstruction with reduced VC. Patients with mixed patterns should therefore be referred to a specialist centre for further investigations.

**Variable and fixed large airway obstruction** often gives rise to strikingly abnormal flow-volume loops. Fixed obstruction causes a so-called ‘hamburger’ pattern (Fig. 10). The inspiratory limb is flattened (horizontal) with variable extrathoracic obstruction, whereas the expiratory limb is flattened with variable intrathoracic obstruction.

### 8.2 Grading

Impaired lung functions are generally graded to quantify respiratory impairment/disability for medico-legal purposes, and to optimise and standardise treatment.\(^2\) Previously, lung functions were graded according to the worst-affected parameter (usually \( \text{FEV}_{1} \) for obstructive impairment and FVC for restrictive impairment).\(^2\) However, the ATS/ERS guidelines suggest grading both obstructive and restrictive ventilatory impairments solely according to \( \text{FEV}_{1} \), as there is little or no evidence for the use of FVC, VC or even TLC as a parameter of impairment.\(^8\) Where appropriate, post-bronchodilator \( \text{FEV}_{1} \) values should be used (Table 7).

Large airway obstruction should not be graded according the \( \text{FEV}_{1} \). Although spirometry is often sufficient for the evaluation of respiratory impairment, this is not always the case. Further investigations may be indicated (e.g. carbon monoxide diffusion capacity (\( \text{DL}_{CO} \)) and/or exercise testing), particularly in patients with clinical evidence of interstitial lung disease, or when a disproportionate degree of dyspnoea is present with a relatively preserved \( \text{FEV}_{1} \) and FVC.

### 8.3 Reporting

Spirometry reports must contain the following:
- subject name, and date and time of testing
- demographics (gender, age and race) and personal information (height and weight)
- origin of reference value (and whether or not a correction factor was used)
- latest calibration date
- numerical values and graphs in order to assess acceptability and repeatability
subject co-operation, provide acceptable and repeatable results, and categorise common abnormalities (taking relevant reference values into consideration).

9.2 Personnel

Pulmonary clinical technologists, general practitioners certified to practise occupational health, specialist physicians and pulmonologists are trained to perform basic spirometry. Pulmonary clinical technologists are competent to perform advanced lung function tests, which are best interpreted by qualified pulmonologists or specialist physicians with an interest in respiratory medicine.

The South African Thoracic Society (SATS) recognises the need to train other healthcare professionals (e.g. nurses) to perform basic spirometry, given the paucity of trained personnel, but cannot endorse the indiscriminate instruction to others. For further information on training opportunities and certification, contact: The Chairman, Spirometry and Training Certification Committee, South African Thoracic Society, PO Box 16433, Vlaeberg, 8018.

Acknowledgements. We thank other SATS council members for their assessment and approval of this manuscript, the pulmonary function technologists at Tygerberg Academic Hospital for providing the spiromgrams, and Carol Lochner, who compiled all the figures.

References

10. Tikoo SK, de Bee M, Beekleke MR. A respiratory survey in a black Johannesburg workforce. Thorax 1994;49:540-546. [http://dx.doi.org/10.1136/thx.49.4.54]

Accepted 29 August 2012.

Table 7. Severity of any spirometric abnormality based on FEV1.*

<table>
<thead>
<tr>
<th>Severity</th>
<th>FEV1 (% predicted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>&gt;70</td>
</tr>
<tr>
<td>Moderate</td>
<td>60 - 69</td>
</tr>
<tr>
<td>Moderately severe</td>
<td>50 - 59</td>
</tr>
<tr>
<td>Severe</td>
<td>35 - 49</td>
</tr>
<tr>
<td>Very severe</td>
<td>&lt;35</td>
</tr>
</tbody>
</table>

*Adapted from Pellegrino et al.*

Note that spirometry is often used to confirm clinical diagnoses, and to grade the impairment, but should never be used in isolation. The final assessment and interpretation of spirometry requires knowledge of medicine and the patient’s full clinical details (e.g. to diagnose COPD), and may also require further special investigations (e.g. radiology, DL( CO), or plethysmography). Pulmonary function technologists and related personnel should therefore reserve the basic interpretation to the categorisation of abnormalities, and not comment on the presence or absence of a clinically relevant disease process.

9. Spirometry training and certification

9.1 Basic skills

Operators must understand the principles of spirometry summarised in this statement, be able to calibrate the equipment, ensure optimal